All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On March 14, 2023, EP0042, a dual FLT3 and Aurora kinase inhibitor, was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) as a treatment for patients with acute myeloid leukemia (AML).1 This follows on from approval by the U.S. FDA of an investigational new drug application for EP0042 in February 2023.2
Patients with AML and mutations in FLT3 are more likely to have a higher risk of relapse and poorer clinical outcomes.1 Preliminary data from the ongoing phase I/II first-in-human trial of EP0042 in patients with relapsed/refractory AML (NCT04581512) as monotherapy and in combination with standard treatments in patients with FLT3 wild-type and FLT3-mutated AML demonstrated a tolerable safety profile alongside disease stabilization.3
IRENE-G: A prospective RCT of nutritional support following allo-HSCT
The AML Hub is pleased to summarize the design and rationale of the IRENE-G trial (NCT05111834; Impact of Resistance Exercise and Nutritional Endorsement on physical performance in...
Orphan drug designation granted to PCLX-001 by the FDA
An update on PCLX-001, a first-in-class, oral, small-molecule N-myristoylation inhibitor currently in clinical development.
Subscribe to get the best content related to AML delivered to your inbox